Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Senate Sponsors Push Back Vote On Balanced Billing Legislation To Autumn

Executive Summary

A US Senate vote on so-called “surprise” billing and balanced billing legislation will have to wait until after Labor Day in September to allow for consideration of more senators’ input, bill sponsors Lamar Alexander and Patty Murray announced on 24 July.

You may also be interested in...



Industry Advocacy Group Goes Global After Device Tax Repeal

After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.

Device-Related Procedure Costs To Be Revealed Under CMS Proposed Payment Rule

US hospitals would have to reveal on a public website their standard charges and insurer-negotiated prices for a long list of device-related procedures, advanced imaging scans, and lab tests under a proposed Centers for Medicare and Medicaid Services rule released on 29 July.

New US State And Proposed Federal Laws Would Stop Specialists From Balance Billing

A crop of new US consumer protection state laws and proposed federal legislation is aimed at stopping medical specialists from the practice of balance billing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel